Safety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to 4 years

The objective of this study was to assess the safety of adalimumab in patients aged 2 to <4 years old or ≥4 years old weighing <15 kg with moderately to severely active polyarticular juvenile idiopathic arthritis (JIA). Clinical effectiveness and pharmacokinetics (PK) of adalimumab were also e...

Descripción completa

Detalles Bibliográficos
Autores principales: Kingsbury, Daniel J., Bader-Meunier, Brigitte, Patel, Gina, Arora, Vipin, Kalabic, Jasmina, Kupper, Hartmut
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer London 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4161937/
https://www.ncbi.nlm.nih.gov/pubmed/24487484
http://dx.doi.org/10.1007/s10067-014-2498-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4161937/
https://www.ncbi.nlm.nih.gov/pubmed/24487484
http://dx.doi.org/10.1007/s10067-014-2498-1

Ejemplares similares